Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome

2013 ◽  
pp. 15-31
Author(s):  
Beatrice C. Lupsa ◽  
Silvio E. Inzucchi
BMJ ◽  
2019 ◽  
pp. l1114 ◽  
Author(s):  
Esra Karslioglu French ◽  
Amy C Donihi ◽  
Mary T Korytkowski

Abstract Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome (HHS) are life threatening complications that occur in patients with diabetes. In addition to timely identification of the precipitating cause, the first step in acute management of these disorders includes aggressive administration of intravenous fluids with appropriate replacement of electrolytes (primarily potassium). In patients with diabetic ketoacidosis, this is always followed by administration of insulin, usually via an intravenous insulin infusion that is continued until resolution of ketonemia, but potentially via the subcutaneous route in mild cases. Careful monitoring by experienced physicians is needed during treatment for diabetic ketoacidosis and HHS. Common pitfalls in management include premature termination of intravenous insulin therapy and insufficient timing or dosing of subcutaneous insulin before discontinuation of intravenous insulin. This review covers recommendations for acute management of diabetic ketoacidosis and HHS, the complications associated with these disorders, and methods for preventing recurrence. It also discusses why many patients who present with these disorders are at high risk for hospital readmissions, early morbidity, and mortality well beyond the acute presentation.


2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Yu Shan Tseng ◽  
Bradley Tilford ◽  
Usha Sethuraman ◽  
Katherine Cashen

Although most children with coronavirus disease 2019 (COVID-19) are asymptomatic or only with mild symptoms, many symptomatic children still require admission to the intensive care unit. Multiple cases of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic syndrome (HHS) associated with COVID-19 have been reported in adults. However, to our knowledge, only few similar cases have been published in the pediatric population. We report one of the first few severe cases of mixed HHS with DKA associated with COVID-19 in an adolescent. Our patient was successfully treated with intravenous immunoglobulin, Remdesivir, and methylprednisolone. As the pandemic continues, clinicians should be aware of this syndrome and consider early use of Remdesivir and corticosteroids. Further studies are required to understand the pathophysiology of this syndrome occurring with COVID-19.


2000 ◽  
Vol 248 (6) ◽  
pp. 511-517 ◽  
Author(s):  
F. A. W. Kemperman ◽  
J. A. Weber ◽  
J. Gorgels ◽  
A. P. Van Zanten ◽  
R. T. Krediet ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document